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This manuscript collects some papers (two already published and one other waiting for 
submission) on hypertrophic cardiomyopathy (HCM) produced during my PhD program, linked 
together by the same leading thread working to demonstrate the relationship existing between 
myocardial ischemia and fibrosis,  both  hallmarks of the  disease.  
INTRODUCTION 
HCM is a genetic disorder that is typically inherited in an autosomal dominant fashion. There are 
defects in several of the genes encoding for the sarcomeric proteins, such as myosin heavy chain, 
actin, tropomyosin, and titin. Multiple mutations have been identified, with genotype-specific risks 
for mortality and degree of hypertrophy . The disorder has a variable clinical presentation and 
carries a high incidence of sudden death.  HCM is the leading cause of sudden cardiac death in 
young population . However, many patients may remain stable over long periods of time and then 
suddenly they may present adverse events: unexpected death, embolic stroke, and the 
consequences of heart failure . 
The disease is characterized by an inappropriate myocardial hypertrophy, often asymmetrical, and 
occurs with no obvious inciting hypertrophy stimulus . Hypertrophy can occur in any region of the 
left ventricle but frequently involves the interventricular septum, which sometimes results in an 
obstruction of flow through the left ventricular outflow tract (LVOT) . At histology, myocardial 
disarray and islands of fibrosis are considered hallmarks of this disease . The systolic function of LV 
is preserved until the end-stage of the disease, but the thickened myocardium with fibrosis 
increases the stiffness of LV chamber causing impaired diastolic relaxation which produces atrial 
enlargement and may promote atrial fibrillation . At the end stage, the loss of myocites, replaced 
by gross scar, is sufficient to determine a manifest systolic LV dysfunction . Myocardial scars create 
a potentially arrhythmogenic substrate and may increase susceptibility to ventricular 
tachycardias/fibrillation . Indeed, gross macroscopic scarring is frequently present on post-mortem 
examination in HCM patients who  died suddenly, suggesting a possible causal association 
between fibrosis and malignant arrhythmias . 
In most patients with HCM, dense focal myocardial fibrosis can also be visualized noninvasively 
with the use of gadolinium-enhanced cardiac magnetic resonance imaging (LGE-CMR) . Recently, 
some studies demonstrated the prognostic role of fibrosis, expressed as late gadolinium 
enhancement (LGE), as predictor of myocardial death . In addiction is also possible to quantify 
extent of LGE in the myocardium of these patients .  
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The diagnosis of HCM is usually performed at relatively young age when not significant stenosis 
are present in the main coronary arteries. Despite this, many studies showed the importance of 
myocardial ischemia, probably also due to microvascular disease, as cause of myocardial fibrosis 
and symptoms and as a trigger of ventricular arrhythmias  . Infact the assessment of myocardial 
ischemia in selected patients with HCM (with preserved LV function) may represent a prognostic 
tool for identifying those patients at risk for profound disease progression.  
CMR also allows to evaluate myocardial perfusion and quantify non invasively myocardial blood 
flow . 
It’s now clear the importance to study both and individually myocardial fibrosis and ischemia, and 
to evaluate the relationship between myocardial scar, myocardial blood flow and clinical 
expression of the disease. 
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1) Myocardial blood flow and fibrosis in hypertrophic cardiomyopathy 
(J Card Fail. 2011 May;17(5):384-91) 
 
In the first study I investigated the relation between myocardial blood flow (MBF), fibrosis, risk 
factors for sudden death and clinical manifestations in HCM. To strengthen the relationship 
between microvascular abnormalities and myocardial fibrosis I performed the analysis on  two 
different models of hypertrophy: HCM and cardiac acromegalic population study,  as a model of 
organized myocardial hypertrophy, without disarray  and, as we previously demonstrated, with 
the absence of  detectable LGE . Therefore the  purposes of the study were: a) to evaluate the 
association between MBF and the extent of fibrosis in patients with HCM by cardiac magnetic 
resonance (CMR); b) to assess the relation between MBF and fibrosis with  "clinically established" 
risk factors for sudden death; c) to demonstrate the role of a reduced MBF and the presence of 
LGE in HCM for the occurrence of symptoms. CMR with velocity-encoded phase contrast 
technique (PC-CMR) is a validated method to quantify blood flow . Coronary sinus blood flow 
constitutes 96% of the total venous drainage of coronary blood flow. Thus, quantification of 
coronary sinus flow by PC-CMR is an alternative way to assess myocardial blood flow (MBF) 
without exposing patients to ionizing radiation. Previous studies demonstrated excellent 
agreement between myocardial PET and PC-CMR for the quantification of MBF .  
METHODS 
Patient Population 
A total of 64 consecutive patients with HCM (45  males, mean age of 47±16 years) were enrolled in 
the study from January 2007 to June 2009. The diagnosis of HCM was based on previously-
reported criteria .  
As a model of left ventricular hypertrophy non-HCM, we included patients with cardiac 
acromegaly: from an initial population of 35 consecutive patients with untreated active 
acromegaly who underwent CMR, we selected 15 patients (9 male, 47+-12 years old)  having left 
ventricular mass index higher than the referral range.  Twenty healthy, normal subjects (14 males, 
mean age of 48 ± 10 years) were enrolled as a control group.  
To exclude the presence of coronary artery disease, we included in HCM  and in acromegalic 
population patients with a negative coronary angiography, or a negative exercise test or a low 
(<10%) 10-year risk for coronary events . The study was approved by the internal ethical 
committee of our institute.  
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The following markers of increased risk of sudden death in patients with HCM were evaluated: 
family history of sudden death, extreme left ventricular (LV) wall thickness (≥ 30 mm), unexplained 
(non vasovagal) syncope, and non-sustained ventricular tachycardia (VT) on ambulatory ECG 
Holter recordings (> 4 ventricular beats). By clinical interrogation, each patient was classified in a 
NYHA class, assessed by a physician blinded to CMR data, on the basis of the presence and the 
severity of dyspnea before the CMR examination. The history of other symptoms (chest pain, 
palpitation) was also recorded. A 12-lead resting electrocardiogram was recorded on the day of 
the CMR examination. The presence of LV outflow tract obstruction was evaluated by 
echocardiography and defined as an LV outflow gradient  ≥30 mmHg. 
Magnetic Resonance acquisition protocol 
CMR study was performed with a dedicated 1.5 Tesla (Signa Hdx, General Electrics Healthcare, 
Milwaukee, Wisconsin) with a 8 channel cardiac phased array coil. 
Short axis cine images from the mitral plane valve to the left ventricular apex were acquired using 
a  steady-state free precessing (FIESTA) pulse sequence with the following parameters: 30 phases,  
slice thickness 8 mm, no gap, views per segment 8, NEX 1, FOV 40 cm, phase FOV 1, matrix 
224x224, reconstruction matrix 256 x 256, a 45° flip angle, TR/TE equal to 3.5/1.5, and a 
bandwidth of 125 KHz.  
Coronary sinus flow was obtained acquiring images orthogonal to the coronary sinus, using 
imaging planes as close as possible to the right atrium, to include as many posterior cardiac veins 
as possible. A free breathing velocity-encoded phase contrast gradient-echo cine sequence with 
cardiac and respiratory gating was used.The following parameters were applied: TR/TE 12/5 msec, 
flip angle 20°, field of view 30, phase field of view 1, matrix 192x160, reconstruction matrix 
256x256, slice thickness 5 mm, number of excitation 5.  Flow sensitivity was set to 50 cm/sec of 
encoded velocity and raised if aliasing artifact occurred. By the respiratory gating the image data 
were phase reordered to minimize respiratory artifact. The use of free breathing velocity-encoded 
phase contrast technique was previously validated by the comparison with flow probe 
measurement in coronary sinus and in coronary artery .  
LGE technique was used to evaluate the extent of myocardial necrosis. LGE images were acquired 
in short axis views from mitral plane valve to the left ventricular apex by a 2D segmented 
inversion-recovery-prepared gradient echo pulse sequence.  
Images were acquired 10 minutes after administration of Gd-DTPA ( Magnevist, Schering-AG) with 
a dosage of 0.2 mmol/kg in short axis views. The following parameters were used: field of view 40 
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mm, slice thickness 8 mm, no gap between each slice, repetition time 4.6 msec, echo time 1.3, flip 
angle 20°, matrix 224 x 192, reconstruction matrix 256 x 256, number of excitation 1, R-R interval 
2. The appropriate inversion time was set to null normal myocardium (range 250-350 
milliseconds). 
At the end of the examination, a phantom was placed in the CMR scanner and a  velocity-encoded 
fast contrast gradient-echo cine sequence was acquired with the same acquisition plane and 
parameters used for the patient . 
Image post-processing 
Analysis of MRI images was performed using a commercially available research software package 
(Mass Analysis, Leyden, The Netherlands). Left ventricular (LV) mass was measured by the analysis 
of the cine short axis images. The endocardial and epicardial contours of LV myocardium were 
traced in the end-diastolic and the end-systolic phase. End-diastolic volume index (EDVi), end-
systolic volume index (ESVi) and mass index were measured as previously described .  
The volumetric data of LV and right ventricle (RV) were plotted against the time (in msec) in a 
volumetric filling time curve. LV diastolic parameters were calculated from the volumes/time 
curve as previously described . Briefly, a dV/dT curve was generated as the first derivative 
transformation of the volumetric filling time curve. The early (E) and late (A) peak filling rate (PFR) 
were measured in dV/dT curve as, respectively, the early and the late diastolic peak of dV/dT 
curve. The PFR E/ PFR A ratio was defined as the ratio between the early and the late peak filling 
rate. 
Mitral regurgitant volume was measured as the difference between LV and RV stroke volumes.  
Coronary sinus flow was measured as previously described . Briefly, the coronary sinus contour 
was traced first on the magnitude images at each cine frame. Then the traced region of interest 
was applied on the corresponding phase image (figure 1). The effect of through-plane motion 
caused by cardiac contraction in the oblique coronary plane was relatively small. However, phase-
offset errors were minimized, for each cardiac phase, by subtracting the signal from the phase 
images acquired in the phantom at the end of the CMR examination. Cross-sectional area of the 
coronary sinus was measured in the magnitude images throughout the cardiac cycle. Mean flow 
velocity of coronary sinus was obtained in the respective phase image. Blood flow was calculated 
as the product of area and mean flow velocity in each cardiac phase. Coronary sinus was 
multiplied for the heart rate, obtaining the coronary sinus flow/minutes. The MBF was calculated 
as coronary sinus flow/minutes divided by LV mass and expressed as ml/min/g. 
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The extent of LGE was measured as previously described . A region of interest (ROI) was selected 
in the background of the image. Mean signal intensity and standard deviation (SD) of this ROI were 
measured. The LV myocardium was delimited by endocardial and epicardial contours traced 
manually. Enhanced myocardium was defined as myocardium with a signal intensity of ≥ 6 SDs 
above the mean of the ROI. The extent of LGE was expressed as percentage of the LV mass. LGE 
was defined undetected when the measured extent was <0.1% of LV mass.  
 
 
Figure 1. Coronary sinus flow measurement. Cross-sectional coronary sinus area was traced in all 
of the magnitude images (top left), and identical area is automatically traced in phase images (top 
middle). Blood flow was calculated as the product of cross-sectional area and mean flow velocity 
in each cardiac phase (bottom left). In the same patient, areas of late gadolinium enhancement 
were detected, as evidenced in a short-axis image (top right) and in its parametric map (bottom 
right). 
 
 
 
 
 
 
 
8 
 
Statistical analysis 
All data were analysed using JMP® software (version 4.0). Data are presented as continuous 
variables and proportions (percentages). Continuous variables are expressed as means ± 1 SD. 
Categorical variables were compared by Pearson chi-square test or Fisher's exact test when 
appropriate. One-way  analysis of variance or Bonferroni post-hoc test, when appropriate, were 
used to compare quantitative variables across groups. A p value <0.05 was considered statistically 
significant. A multiple regression analysis, including MBF as dependent and the presence of LGE, 
the extent of LGE, the maximal end-diastolic wall thickness, history of atrial fibrillation and the age 
as independent variables, was performed with a stepwise selection procedure to assess the 
predictors of MBF in HCM population. Logistic regression analysis with a stepwise selection 
procedure (p < 0.05 for entry; p > 0.10 for removal) was used to evaluate the influence of 
covariates on NYHA class >I.  A Bland-Altman plot was used to evaluate the inter-observer 
reproducibility of the MBF measurement (figure 2) performed by two blinded observators. 
 
 
 
 
 
Figure 2. Bland-Altman plot for the interobserver reproducibility of the measurement of 
myocardial blood flow (left) and the scatter diagram (right panel) showed good agreement 
between the observers. 
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RESULTS 
The clinical characteristics of the HCM  patients are summarized in Table 1. Coronary angiography 
was  performed in 35 patients. Ischemic provocative test was performed in 12 patients. In 17 
patients, aged <30 years, with an estimated risk of  coronary artery disease lower than 10%, no 
ischemic provocative test were performed. Two patients were excluded because of the presence 
of coronary artery disease, found by angiography. The final population included 62 patients with 
HCM. In the acromegalic patients mean serum GH and IGF-1 concentrations were 7.1±9.9 µg/l and 
736±222 µg/l, respectively. As  evidenced in table 1, LV  mass index was significantly higher in HCM  
than in controls but not significant different between HCM and acromegaly patients. 
Acromegaly patients had higher LV mass index than controls (92± 30 vs 74±25 g/m2, p<0.05). 
Resting MBF was significantly lower in patients with HCM than in controls (0.56±0.28 vs 0.92±0.5  
ml/g/min, p<0.04, figure 3).  MBF was also significantly lower in patients with HCM than in 
acromegaly patient.  
LGE was detected in 39(63%)  patients with HCM and in none of the acromegalic patients and 
controls. HCM patients with and without detectable LGE were similar for age (respectively 45±14 
vs 48±18 years, p 0.45) and gender (male 71% vs 73 % respectively). MBF was lower in HCM 
patients with positive LGE than in those with negative LGE (0.46±0.2 vs  0.66±0.29 ml/g/min 
p0.005) (fig. 3B). Patients in HCM group without LGE had lower MBF than controls (p 0.04). For 
multiple regression analysis the independent predictors of MBF were the presence of LGE (p 0.03, 
coefficient -0,025) and the LV mass index (p 0.012, coefficient -0,004).   
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Table 1: Clinical  variables of the HCM population 
 
Variables Controls p 
value* 
HCM p 
 value** 
Acromegaly 
      
 
number 
Age (years) 
Male (n) 
 
Familiar history of HCM n(%) 
 
20 
48±10 
14(70%) 
 
- 
 
 
0.79 
0.94 
 
62 
47±16 
45(72%) 
 
6(10%) 
 
 
0.99 
0.52 
 
15 
47±12 
9(60%) 
 
- 
      
Risk factors for SCD  n(%):      
Familiar history of SD -  3(5%)  - 
Maximal wall thickness ≥30mm -  1 (2%)  - 
Outflow pulse gradient >30 mmHg -  15 (24%)  - 
Unexplained syncope -  4(6%)  - 
VT at 24-Holter monitoring -  10(16%)  - 
      
Clinical manifestation  n(%):      
Angina -  15(24%)  - 
Palpitation -  15(24%)  - 
Dyspnea   NYHA class ≥II 
                 NYHAclass  II 
                 NYHA class III 
-  41 (66%) 
38(61%) 
3(5%) 
 - 
History of atrial fibrillation -  9(44%)  - 
      
CMR findings: 
Maximal end-diastolic thickness (mm) 
LV mass (g) 
LV mass index (g/m
2
) 
LV end-diastolic volume index (ml/m
2
) 
LV ejection Fraction (%) 
LV ejection Fraction <50% n(%) 
Extent of LGE (% of LV mass) 
MBF (ml/min/g) 
 
Therapy n(%): 
 
8±3 
129±30 
74±25 
86± 11 
64±5 
0 
0 
0.92±0.5 
 
 
 
<0.0001 
<0.0001 
0.01 
0.5 
0.06 
 
 
0.04 
 
20±5 
197±54 
104±28 
80± 16 
69±8 
4(6%) 
9.4±13.5 
0.56±0.28 
 
26 (42%) 
 
<0.0001 
0.06 
0.18 
0.24 
0.18 
 
 
<0.0001 
 
13±8 
167±60 
93±30 
85±9 
66±7 
0 
0 
1.36±0.5 
Beta blockers -  21(34%)  - 
Calcium-antagonist -  4(6%)  - 
ACE-inhibitors -  7(11%)  - 
Diuretic -  5(8%)  - 
Anti-arrhythmic -  1(1.6%)  - 
      
 
HCM, hypertrophic Cardiomyopathy;  SCD, sudden cardiac death; VT, ventricular tachycardia; ACE, 
angiotensin converting enzyme; LGE, late gadolinium enhancement; MBF, myocardial blood flow; * p 
value  controls vs HCM; ** p value of HCM vs acromegalic patients. 
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Risk factors and MBF 
MBF was not significantly different in patients with than in those without familyhistory of sudden 
cardiac death (0.41±0.07  vs 0.57±0.3 ml/g/min, p 0.31). Patients with unexplained syncope had 
significantly higher MBF (0.91±0.1 vs 0.55±0.3 ml/g/min, p<0.02). MBF was lower in patients with 
at least one risk factor than in patients without any risk factors ( 0.48±0.27 vs  0.63±0.27 ml/g/min, 
p<0.05).  
At 24 hours ECG Holter monitoring VT was recorderd in 10 (16%) patients. As showed in table 2  
patients with VT had significantly lower MBF than patients without. Yet, patients with non-
sustained VT had significantly higher extent of LGE, higher maximal end-diastolic thickness and 
total risk score.  
 
Table 2: Occurrence of VT in population with HCM 
 
Variables 
 
Non-sustained VT 
 
Absence of  
non-sustained VT  
      
p-value 
    
Patients      10 52  
Male 7 (70%)            37(74%)  
Age ( year)  53 ± 12  46 ± 16    0.09 
 
Risk factors for SCD:                  
                                 
Familiar history of SCD                0 3 (5%)                          
Unexplained syncope                      3 (5%)                                         0   0.5 
Maximal  end-diastolic wall thickness (mm) 23 ± 3                          19 ± 5          0.05 
Outflow pulse gradient  (mmHg)             16 ± 25                                        15 ± 26                 0.9 
Total risk score(n. of risk factor per SCD)               1.6 ± 0.9                           0.4 ± 0.6 <0.01 
 
CMR: 
   
Extent of LGE (% of LV mass) 29.3 ± 4.5                    7.3 ± 1.9       <0.0001                          
MBF (ml/g/min)                        0.4 ± 0.14                 0.6 ± 0.29 <0.04 
LV mass  index (g/m2)             109 ± 24                          104 ± 29             0.9 
LV ejection fraction (%)          66 ± 11                             70 ± 8               0.34 
PFR E (ml/sec) 319± 169 398± 280    0.5 
PFR A (ml/sec) 211± 101 229± 95            0.7 
PFR E/PFR A  3.4± 4.1 1.9± 1.2        0.2 
    
    
VT, patients with episode of ventricular tachycardia at 24-hours Holter monitoring; no-VT, patients 
without episode of ventricular tachycardia; SCD, sudden cardiac death; LGE, late gadolinium 
enhancement; MBF, myocardial blood flow; LV, left ventricle; PFR E, peak of filling rate E; PFR A peak 
of filling rate A.  
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Clinical Manifestations and MBF 
The incidence of symptoms in the total population of HCM is showed in table 1.Of the HCM 
population 38 patients were in NYHA class II, 3 in class III e none in class IV.   However, average 
MBF was 0.44±0.22  ml/g/min for patients in  NYHA class II and 0.43±0.2 ml/g/min in class III.  
 Compared with asymptomatic patients, MBF was not different in patients with angina (0.61±0.32 
vs 0.57±0.26  ml/g/min, p 0.8), palpitations (0.61±0.32 vs 0.61±0.3 ml/g/min, p 0.99) and history of 
atrial fibrillation (0.61±0.32 vs 0.57±0.2 ml/g/min, p 0.7). In table 3 the clinical and CMR 
parameters of HCM patients with preserved LV function (ejection fraction ≥50%) are reported. 
This selection of patients have been done to assess the role of reduced MBF and the presence of 
fibrosis in absence of LV dysfunction, as potential cause of dyspnea.  In this selected group of HCM 
patients, those in NYHA functional class ≥ II had  lower MBF than patients in NYHA class I.  
Moreover, the patients in NYHA class ≥ II showed a larger extent of LGE, higher maximal end-
diastolic wall thickness, greater left atrium and higher mitral regurgitant volume than the patients 
in NYHA class I. Furthermore, the patients in NYHA functional class ≥ II had significantly lower PFR 
A. In the logistic regression model, including MBF, extent of LGE, age, maximal LV wall thickness 
and left atrial diameter,  MBF was the only  independent predictor of NYHA >I (coefficient 5.8, 
standard error 2.37, p 0.01). 
DISCUSSION 
The main results of this study could be synthesized as follows: 1) resting MBF was significantly 
lower in HCM than in controls and in patients with acromegalic LV hypertrophy; 2) patients with 
HCM presenting fibrosis as detected by LGE showed lower MBF than those without; 3) an 
association between non-sustained VT and MBF was found in this population 4) MBF was the only 
independent predictor of worse functional class (NYHA class  
Resting MBF in HCM 
Kawada et al. evaluated MBF by PC-CMR in 29 patients with HCM in resting condition and during 
hyperemia induced by dypiridamole . They demonstrated a reduced hyperemic response to 
vasodilator in HCM patients than in controls, with  a non  significant difference in resting MBF. The 
results of the current study showed that basal MBF was significantly lower in HCM than in healthy 
controls. This could be explained because of the larger size of population in our study than in the 
previous one. Moreover, the selection of patients was different: we enrolled also patients with 
previous history of atrial fibrillation and/or impaired ejection fraction which were excluded in the 
previous study. Patients with HCM complicated by episode of parossistic atrial fibrillation or by 
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decreased EF could be in advanced stage of disease and have lower MBF than those without.  The 
finding of a decreased MBF is concordant with the physiopathologic mechanism of ischemia in  
HCM. In fact, a mismatch between disproportionate LV hypertrophy, lack of capillary growth, and 
abnormally narrowed intramural coronary arteries, were previously demonstrated in HCM and 
could be used to partially justify the reduced supply of blood flow at rest . Myocardial fibrosis 
could participate to the decruitment of capillary vessels, and be involved in decreasing resting 
MBF. Alternatively, replacement fibrosis could be secondary to brief episodes of repeated 
ischemia.   
In this study  the presence of detectable LGE and the LV mass index were independent predictors 
of MBF in HCM.  The mismatch between the coronary flow supply and the increased LV mass may 
result in a reduction of global MBF.  The disproportion between increased mass and flow was an 
intrinsic feature of  HCM  as demonstrated by the comparison with  acromegalic LV hypertrophy .  
We chose LV hypertrophy in acromegaly because it is a model of organized myocardial 
hypertrophy, without disarray  and, as we previously demonstrated, with the absence of  
detectable LGE . 
In age- and sex-matched patients with acromegaly and LV hypertrophy a significant lower maximal 
wall thickness than in HCM was found although the LV mass index was not  different.  Despite 
similar LV mass index,  significant higher MBF than HCM was measured. Then, in acromegaly the 
increased LV mass index was  balanced by a proportionate increase in coronary flow resulting in a 
preserved MBF.  
In this study  we found an association between myocardial fibrosis detected by LGE technique and 
MBF:  patients with HCM and a positive LGE had significantly lower MBF than those with negative 
LGE. These results  suggest a link between fibrosis and MBF, even if it remains unclear whether 
fibrosis is a consequence of myocardial ischemia or it is a direct cause of reduced MBF at rest.  
Resting MBF and ventricular arrhythmias 
Both myocardial fibrosis and transitory ischemia were considered as potential substrate in 
triggering malignant ventricular arrhythmias . In agreement with previous reports, results of the 
current study confirmed the relation between total risk score, the maximal end diastolic wall 
thickness, and the extent of LGE  with ventricular tachyarrhythmias on 24 hours ECG monitoring . 
Moreover, we found that patients with episode of non-sustained VT had significantly lower MBF at 
rest and higher extent of LGE. The occurrence of episodes of non sustained VT at 24 Holter ECG 
monitoring is generally regarded to be an independent determinant of increased risk of sudden 
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death in this disease . Thus, these results highlight the value of LGE as an emerging feature to be 
evaluated in patients with HCM. LGE could be particularly useful to stratify the risk in subjects with 
only one “accepted” risk factor of sudden death .  
Recently, two large studies evaluated the prognostic role of LGE in HCM demonstrating that 
patients with a positive LGE had worse prognosis than those without a detectable LGE  . However, 
LGE was described in most  of HCM patients (60-80% of them) and it may be considered a sensitive 
predictor of worse outcome also taking into account other  parameters such as LGE extent,  the 
pattern of distribution of LGE,  and also the MB to stratify more accurately patients with HCM. 
Thus. the impact on the clinical management  and the prognostic role of  resting MBF in HCM 
should be evaluated by further long-term follow-up studies.  
Resting MBF and NYHA class 
A significant correlation between LGE and impaired functional class (NYHA class ≥ II) has been 
already demonstrated . In this study we also found a reduced MBF in patients with impaired NYHA 
class. The presence of atrial dilatation, the maximal wall thickness and a reduced PFR E were also 
associated  to worse NYHA class. Noteworthy, only MBF was an independent predictor of worse 
functional class. Therefore, it is hypothesizable that effort dyspnea could be secondary to brief 
episodes of ischemia, already documented in HCM patients, and that ischemia could more likely 
occur in patients with a low resting MBF.  
Moreover, previous study showed that subject with impaired MBF were more likely to experience 
LV remodeling with dilatation, wall thinning and systolic disfunction . 
Study limitations 
The main limitation to the current study was the absence of evaluation of MBF during hyperemia. 
However, our results suggest that the evaluation of resting MBF could be useful for the clinical 
stratification in patients with HCM. The prognostic role of impaired resting MBF and coronary 
reserve must be evaluated by further long-term follow-up studies. 
Flow measurement in this study was performed using a free breathing velocity-encoded phase 
contrast pulse, which has been previously validated invasively by  the comparison with the  flow 
probe measurements of coronary sinus and coronary arteries  . Although vessel contours may be 
blurred with this approach owing to motion artifacts, in same time, the potential of using multiple 
averages (NEX = 5)  increases  signal-to-noise ratio thus improving image quality.  Yet, flow 
evaluation during free breathing acquisition may be considered more physiological than the 
acquisition during long breath-holding. Moreover, as showed in table 1, most of the HCM patients 
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assumed beta-blockers or calcium antagonist therapy and the heart rate was usually around 50-60  
bpm. In these patients the acquisition time of the phase-contrast images was longer, lasting  
usually  >25 seconds and some patients may not be able to keep a complete breath-holding. 
Regarding the ability of velocity-encoded phase contrast imaging CMR to measure flow specifically 
in small structures. Hofman et al  demonstrated that accurate blood volume flow rates may be 
determined through small vessel for a number of voxels per vessel diameter value of about ≥3. In 
the present  study, we found an average coronary end-systolic diameter of  9±2  mm and end-
diastolic diameter of 6±1 mm. Coronary sinus cross section is usually ovoid and the minor 
diameter is usually oriented in superior-inferior direction and  the maximal diameter is anterior-
posterior. In our protocol of acquisition of coronary sinus images, the frequency direction is 
usually in the superior-inferior direction and the phase in anterior-posterior in order to avoid the 
wrap-around artifact. Thus, despite a voxel dimension of 1.6 mm x 1.9 mm,  the number of voxels 
in each direction is usually >3. Moreover, the net flow in coronary sinus is mostly evidenced during 
the cardiac phase when the coronary sinus has a larger diameter. Then, the resulting effect of low 
spatial resolution may be minimal. The coronary sinus diameters in this study was slightly higher 
than those found by van Rossum et al.  but this may be secondary to the difference in age of 
population, older in our study, or to the improved quality of cine images with 1.5T scanner.  
CONCLUSIONS 
CMR may be considered a valuable imaging tool in HCM allowing accurate evaluation of cardiac 
morphology, quantitative measurement of LV mass, wall thickness, detection and quantification of 
fibrosis and the quantification of MBF in resting and hyperemic condition. Moreover, CMR is a non 
invasive, virtually safe technique, without administration of ionizing radiation. Thus, CMR may be 
particularly important for an initial evaluation of patients with a new diagnosis of HCM, and for 
serial evaluation of the progression of this disease. 
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2) Progression of myocardial fibrosis assessed with cardiac magnetic resonance in hypertrophic 
cardiomyopathy. 
(J Am Coll Cardiol. 2012 Sep 4;60(10):922-9) 
 
After the demonstration that during resting conditions patients with myocardial fibrosis had more 
reduced coronary blood flow than those without, I hypothesized that abnormal MBF, caused by 
microvascular dysfunction, was responsible for myocardial ischemia–mediated myocyte death, 
and ultimately for repair in the form of replacement fibrosis. Therefore, I have speculated that 
myocardial fibrosis is a progressive, and not static phenomenon. In addiction, considering the 
prognostic role of fibrosis in HCM, it is fundamental to understand this pathological process.  
Objectives of this second study were: a) to assess the amount and rate of progression of LGE by 
two consecutive CMR examination ; b) to evaluate the relationship between the rate of 
progression of LGE and clinical variables. 
METHODS 
Population 
We enrolled a total of 70 consecutive patients with a diagnosis of HCM, in sinus rhythm  without 
contraindications for CMR. All these patients underwent to a first CMR examination (CMR-1). After 
CMR-1,  15 patients were excluded: 2 patients for known significant coronary artery disease, 8 
patients for ICD implantation, 2 patients for permanent atrial fibrillation (occurred after CMR-1), 1 
patient for septal myectomy, and finally 2 patients for non-sufficient quality of images. The final 
population who completed the serial CMR examinations were 55 patients . The study was 
approved by the internal ethical committee of our institute and all subjects gave their written 
informed consent. The authors of this manuscript have certified that they comply with the 
Principles of Ethical Publishing in the International  . 
All the patients enrolled underwent clinical, electrocardiographic, and echocardiographic 
evaluation at the time of the CMR-1 and CMR-2.  The diagnosis of HCM and assessment of the LV 
ouflow gradient were based on previously reported echocardiographic criteria . The conventional 
primary prevention risk markers for sudden death in HCM were evaluated: family history of 
sudden death, extreme left ventricular (LV) wall thickness (> 30 mm), unexplained (non vasovagal) 
syncope, and non-sustained ventricular tachycardia on ambulatory ECG Holter recordings (> 4 
ventricular beats at a heart rate > 120 beats per minute), abnormal ”flat” systolic arterial pressure 
during exercise stress test . A complete clinical evaluation was performed at the enrolment and 
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repeated at CMR-2.  By clinical interrogation, each patient was classified in a NYHA class on the 
basis of the presence and the severity of dyspnoea. The history of other symptoms (syncope, chest 
pain, palpitation) was also recorded. A 12-lead resting electrocardiogram was recorded on the day 
of the CMR examination. An imaging stress test was performed in all the patients. When the stress 
test was positive, evaluation of coronary anatomy was performed by  angiography or  coronary 
computed tomography angiography. Patients with significant coronary artery disease were 
excluded from the study. 
CMR protocol 
CMR was performed with a dedicated 1.5 Tesla (Signa Hdx, General Electrics Healthcare, 
Milwaukee, Wisconsin) with an 8 channel cardiac phased array coil.  Short axis cine images from 
the mitral plane valve to the LV apex were acquired using a  steady state free precessing (FIESTA) 
pulse sequence with the following parameters: 30 phases,  slice thickness 8 mm, no gap, views per 
segment 8, NEX 1, FOV 40 cm, phase FOV 1, matrix 224x224, voxel dimensions 1.78x1.78x8 mm, 
reconstruction matrix 256 x 256, a 45° flip angle, TR/TE equal to 3.5/1.5, and a bandwidth of 125 
KHz.  In both the first and second examinations, LGE images were acquired 10 minutes after the  
administration of Gd-DTPA (Magnevist, Schering-AG) with a dosage of 0.2 mmol/kg in short axis 
views. An inversion recovery T1-weighted  GRE was used with the following parameters: field of 
view 40 mm, slice thickness 8 mm, no gap between each slice, repetition time 4.6 msec, echo time 
1.3, flip angle 20°, matrix 224 x 224, reconstruction matrix 256 x 256, number of excitation 1. The 
appropriate inversion time was set to null normal myocardium (range 250-300 milliseconds) and it 
was the same for both CMR examination.  
Image analysis 
Analysis of CMR images was performed, using a commercially available research software package 
(Mass 6.1, Leiden, The Netherlands). Left ventricular (LV) mass was measured by the analysis of 
the cine short axis images. The endocardial and epicardial contours of LV myocardium were 
manually traced in the end-diastolic and the end-systolic phase. End-diastolic volume index (EDVi), 
end-systolic volume index (ESVi), mass and mass index were measured as previously described . 
Maximal  LV end diastolic wall thickness was measured as previously described  . Comparing the 
two CMR examination, a significant change in LV mass was defined for a measured difference ≥5 
grams. The extent of LGE was measured using a  previously validated method . Briefly, endocardial 
and epicardial contours in each image were manually traced to identify LV myocardium in each 
image. To obtain the standard deviation of the signal noise of the images a region of interest was 
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placed in the background of the image, near the patient's thoracic wall. The mean signal intensity 
and standard deviation were measured in this region of interest.  
Myocardial voxels with signal intensity higher than the average signal intensity of the region of 
interest plus 6 standard deviations were considered enhanced  . The percentage of enhanced 
voxels in the entire LV myocardium was measured. Extent of LGE was expressed in gram and 
percentage of LV mass. A significant increase of LGE was defined when the extent of LGE increased 
of ≥1 gram at CMR-2. This threshold was chosen because in considering the dimensions of the 
voxel,  1 gram of LGE was equivalent to  >50  voxels. The rate of progression of LGE (LGE-rate) was 
defined as the ratio between the increment of LGE extent in grams and the time (months) 
between the two examinations.  Quantification of LGE was performed in a random fashion by 2 
investigators who were blinded to: 1) the clinical information of the patients;  2) the value of LGE 
extent  measured  at CMR-1.     
Statistical Analysis 
Categorical variables were compared by Pearson’s chi-squared test or Fisher's exact test as 
appropriate; the McNemar and the Cochran's tests were employed for analyzing changes in 
patients’ proportions among classes (e.g. NYHA classes) between CMR-1 and CMR-2. Statistical 
tests used to compare groups included paired/unpaired Student’s t test for difference in mean 
values and Mann-Whitney U test or Wilcoxon’s test for skewed variables.  
The Pearson’s correlation coefficient was employed for quantyfing the relationship between 
Gaussian distributed variables; for skewed variables, the logarithmic transformation was applied 
(e.g. LGE values). Simple and multiple linear regression analyses were then conducted for 
quantifying the effect of parameters at CMR-1 in relation to LGE changes at CMR-2. The 
Kolmogorov-Smirnov test was employed to assess normality of data distribution and for the 
residuals of regression models. A p-value <0.05 was considered statistically significant.  
Data are presented as mean ± standard deviation (SD), median and interquartile range (IQR) and 
as proportions with percentage, as indicated. Statistical analyses were performed using Matlab 
(MathWorks, Natick, MA, USA).  
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RESULTS  
Population 
The final population of patients with HCM who completed the serial CMR examinations included 
55 patients. The average interval between CMR-1 and CMR-2 was 719 ± 410 days.  
Clinical characteristics of the study population are summarized in Table 1.  
Thirty-seven patients were males. Age ranged from 14 to 83 years, mean 42.4 ± 17.7 years. 
Of the 55 patients, thirty-five (63.6%) were in NYHA functional class I, 19 (34.5%) in class II and 1 
(1.8%) in class III at the time of the first CMR evaluation.  HCM was obstructive in 5 patients (9%).  
Ten patients had ≥2 arrhythmic risk factors. Three patients had a stress imaging test positive for 
inducible ischemia despite a coronary artery angiography without significant stenosis in the 
epicardial coronary arteries. 
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Table 1: clinical variable of the population in CMR-1 and CMR-2 
 
Clinical  variables 
  
CMR-1 
 
CMR-2 
 
p value 
     
Patients N 55 55 - 
     
Symptoms  N(%)    
Syncope  3(5) 3(5) - 
Angina  12(22) 12(22) - 
Effort dyspnea (NYHA ≥II)  12(22) 20(36) 0.11 
Palpitation  12(22) 16(29) 0.5 
     
Arrythmic risk factors N(%)    
Patients with 0 risk factor   28(51) 27(50) - 
Patients with 1 risk factor   7(13) 6(12.5) 0.99 
Patients with ≥2 risk factors   10(18) 11(20) 0.99 
Maximal end-diastolic wall thickness ≥30  3(5) 4(7) 0.99 
Unexplained Syncope  3(5) 3(5) - 
VT at 24 hours Holter monitoring   7(13) 9(16) 0.8 
Family History of sudden death   4(7) 47) - 
Outflow pulse gradient >30 mmHg   5(9) 6(12.5) 0.99 
Abnormal Pressure Response during effort  1 1 - 
     
Morphofunctional abnormalities:     
History of paroxysmal atrial fibrillation   5(9) 7(13) 0.99 
Atrial dilatation  17(31) 17(31) 0.99 
Reduced ejection fraction (<50%)  1 1 - 
Mitral regurgitation (>mild)   3(5) 3(5) - 
     
CMR findings:     
LV mass index (g/m2)  mean±SD 109.0 ± 23.1 113.1 ± 26.8 0.036 
Maximal end-diastolic thickness (mm)  mean±SD 20.8 ± 5.4 21.7 ± 6.1 0.506 
Ejection fraction (%) mean±SD 68.9 ± 9.6 68.5 ± 9.4 0.923 
End Diastolic Volume index (ml/m2) mean±SD 75.5 ± 17.5 74.5 ± 16.5 0.075 
LGE  detectable  N(%) 45 (81.8%) 53 (96.4%) 0.031 
LGE extent (in grams)  mean±SD 13.3 ± 15.2 24.6 ± 27.5 <0.001 
 median (IQR) 8 (15) 17 (30) <0.001 
LGE extent (% of LV mass) mean±SD 6.2 ±6.6 10.5 ± 10.0 <0.001 
 median (IQR) 4 (7) 8 (12) <0.001 
     
Therapy: N(%)    
Beta-blockers  27 (50%) 32(58) 0.8 
Calcium antagonist  5 (9.1%) 2(5) 0.99 
ACE inhibitors  3 (5.5) 4(10) 0.99 
Diuretic  1 (1.8) 1(1.8) - 
VT, ventricular tachycardia; LV, left ventricolar, LGE, late gadolinium enhancement; ACE, angiotensin converting enzyme. 
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CMR-1 
Measurements obtained at the initial CMR are summarized in Table 1. At CMR-1, LV mass index 
was upper the range of normality in 43 (78.2%) of the study patients. The mean maximal end-
diastolic wall thickness was 20.8 ± 5.4 mm (range 15-38 mm) and was ≥ 30 mm in 3 patients 
(5.5%).  Myocardial hypertrophy mainly involved the interventricular septum and/or the anterior 
free wall in 32 (58.2%) patients of the study population. Hypertrophy was confined in the 
ventricular apex in 10 patients (18.2%) and to the inferior and/or inferolateral wall in 3 patients 
(5.5%).  Finally, hypertrophy was diffuse in 10 patients (18.2%). Mean LV end diastolic volume 
index was 75.5 ± 17.5 ml/m2. Mean LV ejection fraction was 68.9 ± 9.6%, and was ≤50% in only 
one patient (ejection fraction = 37%).  
LGE was detected in 45 (81.8%) of the study patients. The mean extent of LGE was 13.3 ± 15.2 
grams (median and IQR: 8 and 15 grams, range: 1.2 – 84 grams) with a non-Gaussian distribution 
(p<0.001). On average, LGE was identified in 2.3± 1.9 (range 0-6 segments) of the 16 conventional 
myocardial segments into which the myocardium was subdivided. 
CMR-2 
Measurements obtained at the CMR-2 are summarized in Table 1.  LV mass augmented in 30 
patients (54.5%), remained substantially unchanged in 21 (38.2) and decreased in 4 patients 
(7.3%) (Figure 1).  The mean extent of LGE increased from 13.3 ± 15.2 grams at CMR-1 to 24.6 ± 
27.5 grams at CMR-2 (p<0.001).  LV ejection fraction (average 68.5 ± 9.4%) did not change 
significantly from CMR-1 (p=0.923).  
LGE extent increased (≥1 gram) in 44 patients (80%), with a mean increment of 11.3 ± 18.1 grams 
(median and IQR: 6 and 12 grams) (Figure 2). LGE extent unchanged (difference of LGE extent <1 
gram) in 6 patients and decreased in 2. Among the 11 patients without detectable LGE at CMR-1, 
eight patients showed ex-novo LGE at CMR-2 (Figure 3). Thus at CMR-2, LGE was globally found in 
53 (96.4%) patients. In 15 patients (27.3%), the number of myocardial segments with LGE 
significantly increased from CMR-1 to CMR-2, while in 25 patients (45.5%), the increase of LGE was 
confined in the same segments of CMR-1. LGE-rate was 0.54 ± 0.98 (median and IQR: 0 and 1, 
range: 0–6) grams/month.  
During the time interval between the CMR examinations, NYHA class improved from II to I class in 
3 patients who started medical therapy after CMR-1, and worsened in 13 patients (10 from NYHA 
class I to II, 3 from class II to III). Therefore at CMR-2, twenty-three patients were in NYHA class II 
and 4 in class III.  
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LGE increment and clinical correlates 
The increment of LGE extent (logarithmic values) between the two CMR scans was inversely 
related to the age at the enrolment (r = −0.309, p=0.024). The LGE increment was not correlated 
to the time interval between them (r = 0.044, p=0.758) and no difference was observed between 
males and females (12.2 ± 21.5 vs. 9.3 ± 6.8, respectively, p=0.592).  
Patients with apical HCM had a higher increment of LGE (9.4 ± 9.8 vs. 2.9 ± 3.1 % of LV mass, 
p=0.004) and LGE-rate (1.40 ± 1.78 vs. 0.33 ± 0.53 g/months, p=0.001) than those with other 
patterns of hypertrophy, despite a non-dissimilar increase in LV mass (32.0 ± 33.9 vs. 11.8 ± 31.0 g, 
p=0.142); in addition, there was no significant difference in the relationship between LGE at CMR-
1 and LGE rate in the two groups (interaction term p=0.818). Patients with apical HCM had also a 
higher increment of LGE index by the LGE at CMR-1 (2.8 ± 3.0 vs. 0.9 ± 0.9, p=0.002) than other 
patterns.  Patients with worsening of NYHA class had higher increase of LGE extent (13.7 ± 10.8 vs. 
6.1 ± 7.1 grams, p=0.031) and higher LGE-rate (1.15 ± 1.57 vs. 0.40 ± 0.51 grams/month, p=0.049) 
than those with preserved or improved clinical functional status.  
A significant direct relationship between the increase of LV mass index and the increment of LGE 
was observed (r=0.504, p<0.001); furthermore, the increment of LGE was related to the extent of 
LGE at CMR-1 (r=0.498, p<0.001).Differently, LGE increase was not related to the LV mass index at 
CMR-1 (p=0.352), ejection fraction (p=0.068) and the maximal end-diastolic wall thickness 
(p=0.077).  
The apical pattern of hypertrophy and the extent of LGE at CMR-1 were significant independent 
predictors of the increment of LGE between the examinations, in a multivariate model containing 
age as a covariate: the regression model overall explained almost 35% of the variability of LGE 
increase (Table 2). On average, having an apical pattern of  hypertrophy would result in 
approximately 19 grams increase of LGE and 10 grams of LGE extent at CMR-1, would correspond 
to an average increase of approximately 4 grams at CMR-2. 
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Figure 1:  LV mass index at CMR 1 and CMR 2 in the different patterns of HCM 
Left ventricular (LV) mass index was not significantly higher in patients with apical hypertrophic 
cardiomyopathy than in those with other patternsof hypertrophy at CMR-1 (left) and CMR-2 
(right). CMR-1:  first cardiac magnetic resonance examination; CMR-2 :  second cardiac magnetic 
resonance examination. 
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Figure 2: Apical hypertrophic cardiomyopathy at CMR  
Late gadolinium enhancement (LGE) images of a patient with apical HCM at CMR-1 (left) and CMR-
2 (right). Short- and long-axis images clearly show that the extent of LGE increased significantly. 
Abbreviations as in Figure 1. 
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Figure 3: Diffuse hypertrophy at CMR  
LGE images of a patient with diffuse hypertrophy at CMR-1 (left) and CMR-2 (right). At the first 
examination LGE was not detected, at CMR-2 LGE was detected in the anterior and lateral wall. 
Abbreviations as in Figures 1 and 2. 
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DISCUSSION 
HCM is an evolutive disease, so it is intuitive to consider fibrosis a progressive phenomenon, 
however, the rate of progression of LGE was not previously evaluated. In this study we assessed 
for the first time the rate of progression of LGE by repeated CMR examinations in HCM patients.  
The main results were: a) after an average of two years the prevalence of LGE increase from 81.8% 
to 96.4% of subjects and the extent of LGE increased in the majority of them; b)  subjects with 
apical HCM had greater increment of LGE and higher LGE-rate than those presenting other 
patterns of hypertrophy; c) the increment of LGE was higher in patients with NYHA class 
worsening. 
 The presence of LGE in patients with HCM  may be considered relevant in terms of prognostic 
stratification, since recent reports demonstrated that after a clinical follow-up of three years 
patients with LGE had worse prognosis than those without LGE . However, the  specificity of LGE as 
prognostic marker in HCM should be rediscussed  because it is detected in most of the patients at 
the first evaluation and in almost all of them after few years as showed by these results. Then, the 
clinical and prognostic role of other features of LGE as its global extent, the pattern of distribution 
and the rate of progression should be evaluated by further studies in HCM patients.   
In this study we evaluated the increment of LGE between two CMR examinations performed in a 
time range of 719 ± 410 days and calculated a new index, the LGE-rate,  defined as the ratio 
between the increment of LGE in grams and the time in months between the two CMR 
examinations, which represents the rate of progression of LGE over time. LGE-rate was used to 
compare the progression of LGE extent in patients with a different time gap between  the CMR 
examinations. However,  results showed that the increment of LGE was not related to the time 
interval between the two CMR examinations and the rate of progression of LGE was highly 
heterogeneous with a spectrum of values of  LGE-rate ranging from 0.06 to 2.53 g/month.  
Although at CMR-1 the extent of LGE was not different in patients with different patterns of 
hypertrophy  (figure 4), patients with apical HCM  had higher increment of LGE and higher LGE-
rate than other patterns of HCM at CMR-2 (figure 5). Moreover, at multiple regression analysis the 
apical pattern together with the extent of LGE at the first examination were independent 
predictors of the increment of LGE extent.  In a case report, Gebker et al. described a large 
increment of LGE extent in patient with apical HCM between two CMR examinations after a time 
interval of  two years . Several mechanisms may account for the higher progression of fibrosis in 
the apical pattern of LV hypertrophy. The physiological rarefaction of capillar density at the 
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ventricular apex, may participate to the mismatch between oxygen demand and supply in 
hypertrophic apical segments. In fact, Moon et al. demonstrated perfusion defect at the 
hypertrophied segment, representing abnormal myocardial capillary density, in apical HCM 
patients . In patients with apical HCM the development of apical aneurysm may be the extreme 
consequence of the increased fibrosis, shrinkage and severe wall thinning . Yet, myocardial 
infarction appears to be a common complication of apical HCM during long-term follow-up, even 
without significant CAD . Finally, a genetic predisposition may condition the rate of progression of 
fibrosis in apical as well in other patterns of HCM.   
On the clinical point of view, a significant correlation between LGE and impaired functional class 
(NYHA class ≥ II)  was already demonstrated in previous reports . In addition, the current study 
showed a relation between the rate of progression of fibrosis and the clinical status: patients with 
worsened NYHA class had higher increment of LGE and LGE-rate than those with unchanged 
functional status. This result may be explained by the previous observation that impaired diastolic 
function was related to the extent of LGE in HCM  and, consequently,  a positive relation between 
the LGE-rate and the worsening of diastolic function may be hypothesized to justify the 
association between worsened NYHA and LGE-rate.  
Main limitation of this study was the small size of population. This was expected, considering the 
percentage of HCM patients undergoing to ICD implantation after the first CMR and those with 
atrial fibrillation not permitting the acquisition of CMR images because of a non-optimal ECG 
triggering.  
Another limitation was that the coronary artery angiography was performed only in patients with 
a positive exercise stress test. However, 36 patients, with a negative stress test, were aged <45 
years and 17 of them were aged <30 years. The Framingham Risk score demonstrating a < 10% risk 
for coronary artery disease in all the remaining 16 patients . Furthermore, the pattern of 
distribution of LGE in all the patients in the two CMR examinations was not ischemic-like being 
intramural, patchy and non respecting the coronary vessel territory . Yet, in this study genetic 
analysis for the screening of sarcomeric mutations was not performed and further investigations 
are needed to assess whether the rate of progression of fibrosis may be conditioned by a genetic 
predisposition. 
In conclusion, the progression of fibrosis in HCM is very fast, though very heterogeneous, and it is 
faster in apical hypertrophy than in other patterns and it is related to the worsening of the clinical 
status. Therefore CMR can be applied as an useful and safe tool, for longitudinal follow-up 
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evaluation of HCM. However, the clinical and prognostic impact of the LGE-rate, evaluated by 
repeated CMR examinations needs to be assessed by further studies, assessing also whether 
multiple CMR examination over time could be more useful than a “single shot” approach in the 
clinical setting.  
 
 
Figure 4: LGE in different pattern of hypertrophic cardiomyopathy  
The histograms show the extent of LGE in the different patterns of hypertrophic cardiomyopathy 
at CMR-1 (left) and CMR-2 (right): patients with apical hypertrophy had higher extent of LGE at 
CMR-2. Abbreviations as in Figures 1 and 2. 
 
 
Table 2: Multiple regression model for the prediction of increment of LGE extent at CMR-2. 
Predictors  Total R2 = 0.348, p<0.001 
  Beta coef. Beta (STD) p-value Partial R2 
Age (years)  
-0.172 (-0.419 to 
0.075) 
-0.168 0.168 2.6% 
Extent of LGE at CMR-1 (grams)  0.354 (0.072 to 0.636) 0.296 0.015 8.5% 
Apical pattern of HCM  18.63 (7.53 to 29.73) 0.400 0.001 15.1% 
Constant (grams)  10.47 (-2.42 to 23.36) - 0.109 - 
LGE: Late Gadolinium Enhancement; CMR-1: first Cardiac Magnetic Resonance examination; HCM: 
Hypertrophic Cardiomyopathy. The extent of LGE at CMR-1 was expressed in grams, beta 
regression coefficients are reported as mean values with 95% CI.  
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Figure 5: Increments of LGE  
Box and whisker plot showing that the increment of LGE were significantly (*) higher in patients 
with apical pattern than those with diffuse hypertrophy or septal-anterior hypertrophy. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
30 
 
3) Myocardial abnormalities of T2-STIR magnetic resonance in Hypertrophic Cardiomyopathies: 
a predictor of electric myocardial instability.  
(Unpublished data) 
 
In the third study I have assessed the relationship between myocardial fibrosis, clinical status, 
expressed as arrhythmic instability, and tissue edema as sign of myocardial ischemia. Myocardial 
hyperintensity in T2-STIR images (HyT2) on CMR is usually considered as a marker of acute tissue 
damage, most frequently secondary to ischemic or inflammatory insult . HyT2 was also 
demonstrated in a proportion of patients with HCM . Melacini et al., comparing “first pass” 
perfusion, T2-Weighted (T2W)  and LGE images, found that focal tissue abnormalities may 
consistent with regional ischemia at various stages: in the acute phase, the mechanisms leading to 
fibrosis are likely to be cell damage, “focal” edema, and cellular death whereas in the chronic 
phase, for example in patients with perfusion defects but without edema, LGE  is mainly due to 
fibrosis, a tissue with an augmented interstitial matrix. 
Considering that in HCM, myocardial ischemia due to microvascular disease was related to worse 
prognosis   and it is considered as a trigger for arrhythmic events, the aim of my last third study 
was: 1) to prospectively evaluate the association between HyT2 and signs of ventricular electrical 
instability (premature ventricular contraction [PVC], NSVT, heart-rate variability) at 24h-Holter 
ECG monitoring and the arrhythmic risk score; 2) to compare HyT2 with other CMR-derived 
parameters as LGE presence, LGE extent, left ventricular mass index and maximal end-diastolic 
wall thickness. 
METHODS 
Patient Population 
We enrolled consecutive patients with HCM who underwent a CMR examination. The diagnosis of 
HCM was based on previously-reported criteria (17). Sixty-eight HCM patients were consecutively 
enrolled for CMR exam. Out of these, 3 were excluded for low quality of CMR imaging and 1 for 
claustrophobia. Thus the final population consisted of 65 patients (51 males, 49 ± 17 years) who 
completed CMR examination. The study was approved by the ethical committees of our institutes.  
All patients received and signed informed consent. 
Clinical evaluation 
The presence of pre-existing conventional primary prevention risk markers for sudden death in 
HCM were evaluated: family history of sudden death, extreme left ventricular (LV) wall thickness 
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(> 30 mm), unexplained (non vasovagal) syncope, and non-sustained ventricular tachycardia 
(NSVT) on ambulatory  Holter ECG recordings (> 3 ventricular beats at a heart rate > 120 beats per 
minute), abnormal ”flat” systolic arterial pressure during exercise stress test  .  
A 24-hour Holter ECG monitoring was recorded in a time interval between three months before or 
after the execution of CMR examination. 24-h Holter ECG monitoring was recorded for 
conventional and time-domain analysis of heart rate variability: SD of RR intervals, SD of the 
average normal to normal QRS (NN) intervals calculated over periods of 5 min (SDANN); the 
number of interval differences of successive NN intervals >50 ms divided by the total number of 
NN intervals (pNN50); the square root of the mean squared differences of successive NN intervals 
(RMSSD) . 
A complete clinical evaluation was performed in the day of CMR examination. By clinical 
interrogation, each patient was classified in a NYHA class on the basis of the presence and the 
severity of dyspnoea. The history of other symptoms (syncope, chest pain, palpitation) was also 
recorded. A 12-lead resting electrocardiogram was recorded on the day of the CMR scan.  
CMR acquisition protocol 
CMR was performed using two 1.5 Tesla system: a Signa Hdx (General Electrics Healthcare, 
Milwaukee, Wisconsin) and a 1.5 Tesla Magnetom Avanto (Siemens, Erlangen, Germany) with 
cardiac phased array multichannel coils. 
Short axis cine images from the mitral plane valve to the left ventricular apex were acquired using 
a  steady state free precessing pulse sequence with the following parameters: 30 phases,  slice 
thickness 8 mm, no gap, views per segment 8, NEX 1, FOV 40 cm, phase FOV 1, matrix 224x224, 
reconstruction matrix 256 x 256, a 45° flip angle, TR/TE equal to 3.5/1.5.  
T2-STIR images were acquired using triple inversion recovery T2 weighted pulse sequence in short 
axis views and 2 long axis views (vertical and horizontal long axis view) using the following 
parameters: TR = 2 RR, TE ≈70 msec, FOV 40 cm, phase FOV 1, matrix 256 x 256, flip angle  
LGE  images were acquired starting  8  minutes after administration of Gd-DTPA ( Magnevist, 
Schering-AG) with a dosage of 0.2 mmol/kg in short axis views. An inversion recovery T1-weighted  
GRE was used with the following parameters: field of view 40 mm, slice thickness 8 mm, no gap 
between each slice, repetition time 4.6 msec, echo time 1.3, flip angle 20°, matrix 224 x 224, 
reconstruction matrix 256 x 256, number of excitation 1. The appropriate inversion time was set to 
null normal myocardium (range 250-300 milliseconds). 
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Images post-processing 
A commercially available research software package (Mass Analysis, Leyden, The Netherlands) was 
used for the quantification of functional parameters. Left ventricular (LV) mass was measured by 
the analysis of the cine short axis images. The endocardial and epicardial contours of LV 
myocardium were traced in the end-diastolic and the end-systolic phase. End-diastolic volume 
index (EDVi), end-systolic volume index (ESVi), mass and  mass index were measured as previously 
described . LV mass index was  considered severely increased when > 3 SD over upper limit of 
normality . Maximal  LV end diastolic wall thickness was measured as previously described   . T2-
STIR images were evaluated using a qualitative visual assessment and also by a quantitative 
automatic analysis. The visual assessment was performed by three expert independent 
investigators blinded each others. The presence of signal abnormalities (HyT2) was established 
when there was agreement of evaluation in at least 2/3 investigators. 
A complete agreement of the three investigators was reached in the analysis of the images of 95% 
patients.  The quantitative evaluation was performed using a custom software. On short axis 
images a region of interest was placed in remote, non hypertrophied, myocardial segments and 
the mean signal intensity and standard deviation  was measured in this region. Endocardial and 
epicardial contours were manually traced in short axis images and the signal intensity was 
measured in each voxel of images. A curve of distribution of signal intensity was automatically 
generated and myocardium was considered hyperintense when the signal intensity was higher 
than mean 2SD measured in the region interest. The extent of hyperintense myocardium in T2-
STIR images was measured as the percentage of left ventricular mass. 
The extent of LGE was measured using a previously validated method . Briefly, endocardial and 
epicardial contours in each image were manually traced to identify LV myocardium in each image. 
To obtain the standard deviation of the signal noise of the images a region of interest was placed 
in the background of the image, near the patient's thoracic wall. The mean signal intensity and 
standard deviation were measured in this region of interest.  
Myocardial voxels with signal intensity higher than the average signal intensity of the region of 
interest plus 6 standard deviations were considered enhanced . The percentage of enhanced 
voxels in the entire LV myocardium was measured. Extent of LGE was expressed in gram and 
percentage of LV mass. 
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Statistical analysis 
Categorical variables were compared by Pearson’s chi-squared test with the continuity correction 
or Fisher's exact test when appropriate. The Kolmogorov-Smirnov test was used to assess 
normality of data. Pearson’s (r) and Spearman’s (ρ) correlation coefficients were employed for 
Gaussian and skewed variables, respectively. One-way analysis of variance (ANOVA) or Kruskal-
Wallis test, when appropriate, were employed to compare quantitative variables between groups.  
Logistic regression analysis using a forward selection algorithm was used with the HyT2 as 
dependent variable, and LGE extent, left ventricular mass index, maximal end-diastolic wall 
thickness, LV ejection fraction and the number of arrhythmic risk factors as independent variables. 
Logistic regression analysis was also used to explore the impact of each variable in a model with 
the NSVT at 24-hour Holter ECG monitoring as dependent variable, and myocardial abnormalities 
at T2-STIR, LGE presence and LGE extent, left ventricular mass index, maximal end-diastolic wall 
thickness, LV ejection fraction and the number of arrhythmic risk factors (excluding NSVT) as 
independent variables. 
A p-value <0.05 was considered to be statistically significant. Data are presented as continuous 
variables and proportions (percentages). Continuous variables are expressed as means ± SD or 
median with interquartile range (IQR) as indicated. 
RESULTS 
Clinical findings 
As evidenced in table 1, clinical expression was heterogeneous: 31 patients were symptomatic for 
effort dyspnea (26 in NYHA II, 5 in NYHA III); 13 angina; 26 palpitations; 6 syncope.  
All the patients were in sinus rhythm during the examination; however, episodes of paroxysmal 
atrial fibrillation were reported in the clinical history of 16 patients (24%).  None had severe 
valvular abnormalities. 
As conventional risk factors for sudden cardiac death we found: 22 subjects (34%) presented non 
sustained ventricular tachycardia at 24-h Holter ECG monitoring, 11 (17%) familiar history of 
sudden death, and 8 (12%) a maximal end-diastolic wall thickness ≥ 30 mm, none a significant drop 
of arterial blood pressure during exercise ECG. Thirty-six patients had no risk factors for sudden 
death, 18 presented one risk factor, while an arrhythmic risk score ≥ 2 was found in 11 patients. 
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Table 1: Clinical characteristics of the population 
  Global population  Hy-T2 No-HyT2 p value 
       
Population n(%) 65  27(42) 38(58)  
Age (years) mean±SD 49 ± 17  52 ± 14 46 ± 17 0.59 
Male n(%) 51 (78)  22(81) 29(76) 0.84 
LVOT obstruction n(%) 15(23)  6(22) 9(24) 0.98 
History of paroxysmal atrial fibrillation n(%) 16(25)  8(30) 8(21) 0.59 
Reduced ejection fraction (<50%) n(%) 6(9)  5(19) 1(3) 0.08 
       
Arrhyhtmic Risk Factors:       
Family history of SCD n(%) 11(17)  5(19) 6(16) 0.97 
VT at 24h Holter ECG monitoring n(%) 22(34)  21(78) 1(3) <0.001 
Resuscitated SCD  n(%) 0  0 0 ns 
Maximal wall thickness≥30 n(%) 8(12)  7(26) 1(3) 0.02 
Unexplained Syncope n(%) 6(9)  4(15) 2(5) 0.31 
Outflow gradient >30 mmHg n(%) 11(17)  4(15) 7 (18) 0.86 
Abnormal pressure response during 
effort n(%) 0  0 0 ns 
Patients with 0 risk factors n(%) 36(55)  3(11) 33(87) <0.001 
Patients with 1 risk factors n(%) 18(28)  14(52) 4(11) <0.001 
Patients with≥2 risk factors n(%) 11(17)  10(37) 1(3) <0.001 
       
Symptoms:       
Angina n(%) 13(20)  7(26) 6(16) 0.42 
Syncope n(%) 6(9)  4(15) 2(5) 0.31 
Palpitation n(%) 26(40)  17(63) 9(24) 0.002 
Dyspnea n(%) 31(52)  10(37) 21(55) 0.18 
NYHA class II n(%) 26(40)  14(52) 12(32) 0.17 
NYHA class III-IV n(%) 5(8)  3(11) 2(5) 0.69 
       
24h ECG Holter monitoring:       
PVC 
median(IQR
) 37 (9-505)  33(14-1253) 41 (8-474) 0.74 
NSVT n(%) 22  21 1 <0.001 
SDNN (ms) mean±SD 130 ± 51  110 ± 38  154 ± 64 <0.01 
SDANN (ms) mean±SD 95 ± 25  86 ± 25 102 ± 21 0.02 
pNN50(%) mean±SD 8 ± 5  9 ± 6 7 ± 5 0.15 
RMSSD(ms) mean±SD 49 ± 24  48 ± 17 50 ± 30 0.75 
       
Therapy        
Beta-blockers n(%) 35(54)  17(63) 18(47) 0.29 
Calcium antagonist n(%) 5(8)  4(15) 1(3) 0.13 
ACE inhibitors n(%) 17(26)  7(26) 10(26) 0.98 
Antiarrhythmics n(%) 15(23)  8(30) 7(18) 0.52 
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CMR findings 
Summary of CMR results is reported in table 2.  
LV mass index was increased in 44 patients (68%), and it was severely increased (> 3 SD of upper 
limit of normality) in 23 (35%). In six patients (9%), LV systolic dysfunction was found (range: 30-
47%). In two patients (2%), LV dilation was found . 
LGE was positive in 61 patients (93%) with a median extent of 9% of LV mass (IQR: 3-19%). Patients 
with positive LGE had higher end-diastolic wall thickness than those without (p=0.05).  
A linear relation was found between the extent of LGE and LV mass index (ρ=0.27, p=0.03). 
 
Table 2: CMR parameters 
  
Global 
population  Hy-T2 No-HyT2 p value* 
       
       
Population n(%) 65  27(42) 38(58)  
Age (years) mean±SD 49 ± 17  52 ± 14 46 ± 17  
Male n(%) 51(78)  22(81) 29(76) 0.84 
Maximal Wall thickness 
(mm) mean±SD 21 ±6  25 ± 7 19 ± 5 <0.001 
LV EDVi (ml/m2) mean±SD 73 ± 26  76 ± 35 71 ± 16 0.46 
LV ESVi (ml/m2) mean±SD 24 ± 19  28 ± 27 20 ± 9 0.11 
LV Mass index (g/m2) mean±SD 112 ± 40  133 ± 47 98 ± 28 <0.001 
LV ejection fraction (%) mean±SD 69 ± 12  66 ± 15 72 ± 8 <0.05 
RV EDVi (ml/m2) mean±SD 65 ± 17  62 ± 18 67 ± 17 0.27 
RV ESVi (ml/m2) mean±SD 19 ± 8  18 ± 9 19 ± 7 0.76 
RV ejection fraction (%) mean±SD 70 ± 7  70 ± 9 71 ±5 0.63 
LGE presence n(%) 61(94)  26(96) 35(92) 0.86 
LGE extent (% of LV 
mass) mean±SD 11 ± 11  16 ± 12 7 ± 8 <0.001 
 
 
 
 
 
 
 
 
36 
 
T2-STIR , Holter ECG monitoring and clinical variables 
On T2 STIR images HyT2 was detected in 27 patients (42%), with no sex (p=0.62) and age (p=0.10) 
differences (figure 1 and 2).   HyT2 was detected in 3/36 (8%) of patients with no arrhythmic risk 
factor, in 14/18 (78%) of patients with one risk factor, in 7/8 (88%) of those with 2 risk factors and 
in 3/3 with 3 risk factors. By logistic regression analysis, the number of arrhythmic risk factor was 
the only predictor of HyT2 (odds ratio – OR: 19, from 5 to 70, p<0.001).  
Subjects with HyT2 had higher LV mass index than those without (133 ± 47 vs 98 ± 28 g/m2, 
p<0.001). The prevalence of HyT2 was higher in case of severely increased LV mass index (26% vs. 
17%, p=0.004). LV EF was lower in patients with than those without HyT2 (66 ± 15 vs. 72 ± 8%, 
p=0.05) and all the patients presenting with systolic dysfunction had HyT2.  
 Patient with HyT2 had greater extent of LGE than those without (16 ± 12 vs. 7 ± 8 % of LV mass, p 
<0.001). 
At 24-h Holter ECG monitoring, 22 (27%) had episodes of NSVT. Patients with NSVT had higher LGE 
extent (18.3 ± 11.9 vs. 6.8 ± 7.9 % of LV mass, p<0.001), higher end-diastolic maximal wall 
thickness (25 ± 6 vs. 19 ±6  mm, p< 0.001), lower LV ejection fraction (64 ± 15 vs. 72 ± 8 % , 
p=0.006), higher LV mass index (131 ± 38 vs. 103 ± 39, p=0.007) and more arrhythmic risk factors 
excluded TVNS (0.6 ± 0.7 vs. 0.14 ± 0.3, p=0.001) than those without NSVT. Non-significant 
differences in age was found between those with and without NSVT (p=0.14).  
Twenty-one patients with NSVT (95%) had HyT2 and only 6 patients with HyT2 had no NSVT at 24-
h Holter ECG monitoring, then patients with HyT2 had higher prevalence of NSVT than those 
without (p<0.001) (figure 3).   
The presence of myocardial enhancement at LGE images was not associated to occurrence of 
NSVT (p=0.35): 39 patients with a positive LGE (64%) had no NSVT but all the patients with NSVT 
had a positive LGE.  
The SD of RR interval and SDANN at  24-hours Holter ECG monitoring were significantly lower in 
patients with HyT2 than those without (110 ± 38 vs. 154 ± 64 msec, p<0.01, and 102 ± 21 vs. 86 ± 
25, p=0.02, respectively).   
By logistic regression analysis,  HyT2 (OR: 165, 11-2455, p<0.001) and LGE-extent (1.1, 1.0-1.3, 
p<0.001) were independent predictors of NSVT at 24-h Holter ECG monitoring. 
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Figure 1. A case of a patient with HCM with HyT2 (arrow in T2-STIR images, left upper panel), 
myocardial fibrosis (arrow LGE images,left lower panel), and pefusion defect (arrow in the frame 
of the first pass gadolinium,  right lower panel)  in the same myocardial segments 
 
 
 
Figure 2:  A case of a patient with HCM having myocardial fibrosis (LGE images, right panel) 
without HyT2 (T2-STIR images, left panel). 
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Figure 3: This patient with HyT2 (left upper panel) and myocardial fibrosis on LGE images (left 
lower panel) had a run of NSVT (right panel). 
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DISCUSSION 
The main results of this study may be summarized as follows: 1) the presence of HyT2 was 
associated with signs of advanced disease consisting of higher LV mass index, lower ejection 
fraction and higher extent of LGE; 3) HyT2 was associated to a higher arrhythmic risk score; 4)  
HyT2 was associated to 24h Holter ECG monitoring parameters of electrical myocardial instability  
(NSVT and decreased heart rate variability); 5) among the CMR-derived parameters,  HyT2 was the 
best predictor of NSTV. 
These results suggest that the presence of myocardial edema in HCM patients is linked to the 
disease progression and electrical instability. 
HyT2 was detected in 95% of  patients with NSVT at 24-hours Holter ECG monitoring. In HCM the 
occurrence of NSVT at ambulatory Holter ECG monitoring is an important arrhythmic risk factor 
and it is also generally considered as marker of increased electric instability in  cardiac diseases .   
The presence of HyT2 was also associated to decreased heart rate variability, suggesting a 
decreased vagal tone which leads to a superiority of sympathetic mechanism and cardiac electrical 
instability.  A low heart rate variability was considered a marker of increased electrical instability 
and it was associated to increased risk of sudden cardiac death in ischemic and non-ischemic heart 
disease . It was previously demonstrated that a depressed heart rate variability was associated to 
arrhythmic events in HCM .  
Etiology of HyT2 
 HyT2 was usually assumed as CMR sign of myocardial edema but its nature was not completely 
demonstrated . In ischemic heart disease myocardial HyT2 was usually considered as myocardial 
edema associated to a prolonged acute ischemic event, that not necessarily produces myocardial 
infarction . In fact, in the setting of acute myocardial infarction, necrotic myocardium was often 
surrounded by areas of transmural HyT2, which represent suffering but viable myocardium, and it 
is used for the assessment of myocardial salvage index . In myocarditis, HyT2 was considered a 
sign of active inflammation and it is usually located in sub-epicardial or in the midwall layer . HyT2 
associated to myocardial infarction usually lasts for one month, whereas, when it is found in 
myocarditis, it may be detected also after 6 months.  
In our HCM patients, HyT2 was located in the midwall of  hypertrophic myocardial segments and it 
was coincident to areas with LGE. Previously, Melacini et al.  hypothesized that these T2 
abnormalities in HCM could be attributed to ischemia caused by microvascular disease, interstitial 
fibrosis, myocardial bridging, impaired diastolic relaxation and mismatch between capillary density 
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and myocardial tissue. In this setting prolonged ischemic events involving the hypertrophied 
myocardial segments may cause small intramural, rather than subendocardial, myocardial damage 
presenting at CMR with both HyT2 and LGE. HyT2 may be detectable in the acute/subacute phase 
but after it may potentially disappear, while LGE may persist as chronic scar.  On other hand, 
Frustaci and colleagues found histopathological evidence of acute myocarditis in a significant 
fraction of their HCM cohort and related this finding to clinical deterioration : in these cases HyT2 
may be expression of inflammatory myocardial damage. Therefore, HyT2 is a marker of acute 
ischemia and inflammation and both injuries are often associated to LGE and may constitute a 
trigger for arrhythmic events. However, the hypothesis of microvascular disease and ischemia as 
the cause of HyT2 is strongly supported by the observation that area of HyT2 closely matched with 
region of hypoperfusion at first pass of gadolinium CMR technique . Moreover, a global decrease 
of myocardial blood flow was previously demonstrated in HCM by CMR and PET studies  . 
Particulary, the extent of LGE was inversely related to the global myocardial blood flow suggesting 
a close relation between ischemic events and chronic myocardial damage . Repeating episodes of 
ischemia could partially explain the relatively fast progression of myocardial fibrosis in HCM, as 
recently demonstrated  . In the current study we detected HyT2 in 42% of patients with HCM. 
Patients with HyT2 had higher LV mass index, lower ejection fraction and higher extent of LGE 
than those without. Moreover, patients with HyT2 had more arrhythmic risk factors than those 
without. All these findings suggest a more advanced disease in patient with HyT2 than in those 
without. Patients with higher LV mass index are more prone to have microvascular disease , a 
lower blood supply/demand ratio and increased interstitial fibrosis. These evidences suggest that 
in a more advanced stage of HCM,  ischemic events may be more severe and prolonged than in 
early stages and potentially cause myocardial damages ranging from a reversible injury, presenting 
as HyT2, to an irreversible cell loss presenting with myocardial fibrosis and eventually depressing 
systolic function. All these factors may represent the substrate of electrical instability which may 
be triggered by a prolonged ischemic events depicted by HyT2 at CMR. As hypothesized in 
Coumel’s triangle theory of arrhythmogenesis, myocardial disarray, fibrosis and hypertrophy are 
arrhythmogenic substrates that necessitate a trigger to induce arrhythmic events. The trigger for 
arrhythmic events may be a prolonged ischemic event, detected by CMR as HyT2. 
HyT2 and LGE 
The presence of LGE in patients with HCM may be considered relevant in terms of prognostic 
stratification.  Recent reports demonstrated that after a clinical follow-up of 3 years, patients with 
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LGE had worse prognosis than those without LGE . However, LGE is usually detected in most of the 
HCM patients at the first CMR evaluation with a reported prevalence of 60-90% .  Then, the 
specificity of LGE as prognostic marker in HCM should be rediscussed. Moreover, once fibrosis 
emerges in the heart its speed of expansion is a relatively fast phenomenon. Recently it was 
demonstrated that the progression of LGE extent is fast in an average follow-up of 2 years . Rate of 
progression of LGE was directly related to a worsening of the clinical outcome of the patients. 
Then, other features as the extent of LGE should be investigated. For this purpose, a recent 
multicenter trial demonstrated that the extent of LGE is a predictor of sudden cardiac death : the 
presence of extensive (>20% of left ventricular mass) and diffuse LGE was currently indicated as an 
emerging new arrhythmic risk factor . However, previous studies showed that an extent of LGE 
>20% of left ventricular mass was related to a loss of sufficient amount of contractile myocites to 
worsen the systolic function    and to contribute to the progression through end-stage disease . 
Results of the current study don’t permit speculations about the long-term prognostic role of Hy-
T2. However, HyT2 which is generally considered a sign of acute myocardial damage, may be 
considered a marker of acute arrhythmic risk. The detection of HyT2 may be potentially relevant 
for clinical management of patients with HCM. Patients with HyT2 may be considered at higher 
risk of arrhythmic events in the short-term period and maybe these patients could benefit by a 
close clinical surveillance. Further studies are needed to assess whether therapeutic adjustment 
may be driven by the detection of HyT2 at CMR. Yet, future studies should be performed to 
investigate about the evolution of HyT2 in HCM. Results of the current study showed a strict 
association between HyT2 and occurrence of NSVT at Holter ECG monitoring and it may be 
interesting to evaluate, by repeated CMR examinations, whether the disappearing of HyT2 might 
be also associated to disappearing of NSVT.   
Limitations 
Some limitations of the current study need to be addressed.  
First, HyT2 may be detected in different conditions as ischemic events, inflammation and other 
acute causes of cardiac damage.  Results of the current study do not allow to understand the 
nature and etiology of HyT2 in HCM. Then, the mechanism of the association between HyT2 and 
ventricular arrhythmias remains unclear.  
Second, we assumed HyT2 in HCM as a sign of acute, transitory, myocardial damage but this 
assumption is based only by the observation of HyT2 in other cardiac disease. Then, further 
studies performing serial CMR examinations should be performed to confirm the reversibility of 
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HyT2 and the evolution of the association between HyT2 and acute electrical instability in HCM 
over time.  
Finally, prognostic role of HyT2 was not evaluated in the current study and further investigations 
should be performed to assess the short- and long-term clinical impact  of this CMR marker in 
larger HCM populations. 
CONCLUSIONS 
In patients with HCM the presence of HyT2 at CMR is associated to more advanced disease and it 
is linked to ventricular arrhythmias and to signs of electrical instability.  HyT2 was detected in 42% 
of patients with HCM and it was the best predictor of NSVT at 24 Holter ECG monitoring. Yet, HyT2 
was associated to depressed heart-rate variability and to a greater arrhythmic risk score.  
Further studies are needed to assess the clinical and prognostic value of HyT2 in HCM and as well 
as also to understand its physiopathologic mechanism and the related potential therapeutical 
implications.  
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